PD
RPRX icon

Point72 (DIFC)’s Royalty Pharma RPRX Stock Holding History

Point72 (DIFC)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,351
Closed -$239K – 2017
2024
Q4 		$239K Sell
9,351
-56,510
-86% -$1.5M 0.01% 833
2024
Q3 		$1.86M Buy
+65,861
New +$1.82M 0.06% 350
2024
Q2 		– Sell
-65,582
Closed -$1.99M – 1846
2024
Q1 		$1.99M Buy
+65,582
New +$1.93M 0.06% 398

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 (DIFC)'s RPRX Position: Q1 2025 in Review

Point72 (DIFC) sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 9,351 shares — an estimated $239K sold.

Point72 (DIFC) first reported a position in RPRX in Q1 2024 and held it in 3 quarters. The position peaked at $1.99M in Q1 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Point72 (DIFC) reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 9,351 Royalty Pharma shares in Q1 2025, an estimated $239K.
  • Point72 (DIFC) first reported a position in Royalty Pharma in Q1 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s Royalty Pharma position peaked at $1.99M in Q1 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.